Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

July 23, 2025

Study Completion Date

February 29, 2028

Conditions
Hypophosphatasia
Interventions
DRUG

ALXN1850

ALXN1850 will be administered via subcutaneous (SC) injection.

DRUG

asfotase alfa

Asfotase alfa will be administered via SC injection.

Trial Locations (21)

4101

Research Site, South Brisbane

21287

Research Site, Baltimore

22030

Research Site, Edirne

25240

Research Site, Erzurum

27705

Research Site, Durham

34899

Research Site, Istanbul

37212

Research Site, Nashville

55455

Research Site, Minneapolis

64108

Research Site, Kansas City

06106

Research Site, Hartford

B7600

Research Site, Mar del Plata

K1H 8L1

Research Site, Ottawa

113-8431

Research Site, Bunkyō City

105-8471

Research Site, Minatoku

565-0871

Research Site, Suita-shi

683-8504

Research Site, Yonago-shi

06230

Research Site, Altındağ

06560

Research Site, Ankara

B4 6NH

Research Site, Birmingham

Unknown

Research Site, Manchester

S10 2TH

Research Site, Sheffield

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY